Erkan Arpaci

Erkan Arpaci

Auto-generated profile, based on publicly available information

Erkan Arpaci

Department of Medical Oncology, Sakarya Adatip Hospital, 54050 Sakarya, Turkey

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Phoenix Medical Journal
Verified
Journal Article
Open access
PDF file
ÖGÖyküm Genç
Öyküm Genç
EAErdi Akar
Erdi Akar
EAErkan Arpaci
Erkan Arpaci
HEHüseyin Engi̇n
Hüseyin Engi̇n
SÇSevim Karakaş Çeli̇k
Sevim Karakaş Çeli̇k
Cytokines are secreted or membrane-bound proteins that act as mediators of intercellular signaling to regulate homeostasis of the immune system. They are produced by cells of innate and adaptive immunity in response to microbes and tumor antigens. Although there are several studies showing that IL2-330 gene polymorphism is associated with many types of cancer, as far as we know, there is a few study investigating the association between lung cancer and IL2-330 gene polymorphism. In this study, the role of IL2-330 gene polymorphism in the pathogenesis of lung cancer was investigated. 96 patients who were diagnosed with lung cancer and 96 age and sex matched healthy subjects participated in the study. Genomic DNA was isolated using the blood DNA isolation kit and the IL2-330 gene polymorphism was determined by polymerase chain reaction-confronting two pairs primer method. When analyzed for the lung cancer group and the healthy group according to IL2-330 gene polymorphism, genotype and allele frequencies were found to be similar in both groups (p>0,05). As a result; there was no statistically significant difference between the groups. Considering the ethnic diversity of lung cancer, the study needs verified in other populations.

Verified
Journal Article
Open access
PDF file
SSSerhat Sekmek
Serhat Sekmek
AOAYSEL OĞUZ
AYSEL OĞUZ
MEMelek Karakurt Eryılmaz
Melek Karakurt Eryılmaz
MAMurat Araz
Murat Araz
SBSedat Biter
Sedat Biter
GUGokhan Ucar
Gokhan Ucar
Background/Objectives: In this retrospective study, we aimed to compare the efficacy, survival, and toxicity results of induction (IC) or adjuvant (AC) treatment with chemoradiotherapy (CRT) in locally advanced nasopharyngeal cancer (NPC). Methods: A total of 405 patients from 22 different centres in Turkey, belonging to the Turkish Oncology Group (TOG), was included. The primary endpoints were overall survival (OS) and progression-free survival (PFS), and the secondary endpoints were safety and toxicity. Results: The median age of the patients included in the study was 49 (18.2–91.5) years. In total, 298 (73.6%) of the patients were male. Of the 405 patients, 258 (63.7%) received IC and 147 (36.3%) received AC treatment. When OS and PFS analyses were performed in terms of age, gender, T and N stages, pathological features, and treatments received, no effect of any variable on prognosis was observed. For the overall group, the median estimated OS was 137.3 months (the Kaplan–Meier statistical method could not reach the 95% confidence interval [CI]). For the IC group, the median estimated survival was 137.3 months (95% CI: 111.4–163.3), whereas the Kaplan–Meier statistical method could not estimate survival for the AC group. No statistically significant difference was observed between IC and AC groups in terms of OS (p = 0.209) or PFS (p = 0.248). Grade 3–4 side effects were observed in 12% of patients in the IC group and 29.9% of patients in the AC group. Treatment was discontinued due to toxicity in 5 patients (1.9%) in the IC group and 18 patients (12.2%) in the AC group. Conclusion: No difference in OS or PFS was observed between AC and IC treatments. More grade 3–4 side effects were observed in the AC-treated group and early discontinuation rate was higher.

10 January 2016 in International Journal of Medical and Pharmaceutical Case Reports
Verified
Journal Article
Open access
EAErkan Arpaci
Erkan Arpaci
SESelcuk Ergen
Selcuk Ergen
YTYasemin Bakkal Temi
Yasemin Bakkal Temi
BBBurak Bahadir
Burak Bahadir
HEHuseyin Engin
Huseyin Engin
Background: In spite of resistance and limited response to chemotherapy, radiotherapy and immunotherapy, recent advances led to several targeted agents that showed the prolongation of progressive free survival. Due to these facts, surgical resection of multiple recurrences may be worthwhile in selected patients with kidney cancer. Case Report: We report a case of a 47-year-old man who underwent nephrectomy for T4N0 RCC, clear cell type, Fuhrman grade 2/4 in 2007. The patient afterward had multiple tumor recurrences. He underwent four metastasectomies, including liver, skin, rectum and scalp. And he received immunotherapy and multiple lines biological targeted treatments. He remains stable for 7 years after initial diagnosis. Conclusion: In patients with metastatic RCC, recurrent resections can be achieved safely and giving biological drugs may prolong survival. Close follow-up is important for the early detection of recurrence and complete resection of metastases can improve the outcomes of patients.